Artelo Biosciences Selects Research Organization for Phase 1b/2a Study

- October 29th, 2019

The company selected Aptus Clinical as the company’s contract research organization for its Phase 1b/2a trial of ART27.13.

Artelo Biosciences (NASDAQ:ARTL) has announced it has selected Aptus Clinical as its research contract research organization (CRO) for its Phase 1b/2a ART27.13 trial.

As quoted in the mpress release:

This latest agreement builds on earlier collaborations between Artelo and Aptus, which included feasibility studies, protocol design, and clinical site identification and selection. The ART27.13 program will continue to be under the operational stewardship of Artelo’s UK subsidiary at the Alderley Park BioHub in Cheshire.

ART27.13 is a highly potent peripherally selective synthetic dual cannabinoid agonist believed to target peripheral cannabinoid receptors sending a feeding message to the brain. The combined Phase 1b/2a trial is expected to enroll up to 49 subjects at clinical sites within the UK. The study is designed to determine the most effective and well tolerated dose in cancer patients and evaluate activity using criteria such as weight gain, lean body mass, and improvement of anorexia.

Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, commented, “We are excited to expand our relationship with Aptus, which will allow us to leverage their broad experience as well as their understanding of local regulatory processes combined with a wide network of investigators and key opinion leaders. We look forward to providing further updates as we commence our Phase 1b/2a trial and advance our cancer anorexia program.”

Steve McConchie, Chief Executive Officer of Aptus Clinical, added, “We are honored to have been selected by Artelo to help oversee this important trial.  Despite the fact that cancer-related anorexia affects about 60% of advanced stage cancer patients, there are no FDA approved drugs for this indication and only a few agents used off-label with limited efficacy.  Clearly, patients deserve better and the profile of Artelo’s product candidate is compelling.”

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply